Vlad Coric, Biohaven CEO
October 4, 2022 03:06 PM EDTUpdated 03:37 PM
Pharma

Vlad Coric charts course for new Bio­haven with neu­ro­science push and Big Phar­ma vets on board

Nicole DeFeudis

Editor

What’s Bio­haven with­out its CGRP port­fo­lio? That’s what CEO Vlad Coric is tasked with de­cid­ing as he maps out the new Bio­haven post-Pfiz­er takeover. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times